Michael J. Kelley, MD

Exciting advances in understanding the biology of lung cancer have occurred over the last few years.

Two different clinical trials using biological agents directed against an autocrine growth factor and a surface marker of neuroendocrine differentiation have been used for patients with relapsed small-cell lung cancer. In a